| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Multiple | D000015 | 13 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Insufficiency | D000309 | 3 associated lipids |
| Akinetic Mutism | D000405 | 1 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alopecia | D000505 | 14 associated lipids |
| Alopecia Areata | D000506 | 6 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Amenorrhea | D000568 | 4 associated lipids |
| Amputation, Traumatic | D000673 | 2 associated lipids |
| Anemia | D000740 | 21 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Anemia, Hemolytic, Autoimmune | D000744 | 5 associated lipids |
| Anemia, Refractory | D000753 | 3 associated lipids |
| Anemia, Refractory, with Excess of Blasts | D000754 | 2 associated lipids |
| Aneurysm, Dissecting | D000784 | 2 associated lipids |
| Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ochiai T et al. | Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. | 1991 | Transplant. Proc. | pmid:1721255 |
| Müller MK et al. | Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. | 1991 | Transplant. Proc. | pmid:1721286 |
| Francavilla A et al. | The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. | 1991 | Transplant. Proc. | pmid:1721287 |
| Woo J et al. | Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. | 1991 | Transplant. Proc. | pmid:1721319 |
| Felser I et al. | Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721350 |
| Alessiani M et al. | CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721351 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Moutabarrik A et al. | FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. | 1991 | Transplant. Proc. | pmid:1721382 |
| Moutabarrik A et al. | In vitro FK 506 kidney tubular cell toxicity. | 1991 | Transplant. Proc. | pmid:1721383 |
| Yamashita T et al. | Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. | 1991 | Transplant. Proc. | pmid:1721414 |
| Van Duyne GD et al. | Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. | 1991 | Science | pmid:1709302 |
| Lim SM and White DJ | The pharmacology of immunosuppression. | 1991 | Ann. Acad. Med. Singap. | pmid:1709344 |
| Lin CY et al. | Effects of FK 506 on the biochemical markers in canine lung allograft rejection. | 1991 | Transplant. Proc. | pmid:1721445 |
| Propper DJ et al. | Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. | 1991 | Transplant. Proc. | pmid:1721446 |
| Murase N et al. | Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. | 1991 | Surgery | pmid:1714104 |
| Nielsen JB et al. | Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. | 1991 | Biochemistry | pmid:2043618 |
| FK 506--an investigational immunosuppressant. | 1991 | Med Lett Drugs Ther | pmid:1716722 | |
| Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
| Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
| MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
| Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
| Brown Z and Neild GH | FK-506 and haemolytic uraemic syndrome. | 1990 | Lancet | pmid:1689442 |
| Thomas J et al. | The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. | 1990 | Transplantation | pmid:1689518 |
| Vathsala A et al. | Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. | 1990 | Transplantation | pmid:1689520 |
| Yamamoto K et al. | Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. | 1990 | Immunology | pmid:1689694 |
| Thomson AW | Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. | 1990 | Transplant. Proc. | pmid:1689883 |
| Zeevi A et al. | Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689884 |
| Morris RE et al. | Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. | 1990 | Transplant. Proc. | pmid:1689885 |
| Francavilla A et al. | FK 506 as a growth control factor. | 1990 | Transplant. Proc. | pmid:1689912 |
| Mazzaferro V et al. | Studies of the hepatotrophic qualities of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689913 |
| Kay JE et al. | The mechanism of action of FK 506. | 1990 | Transplant. Proc. | pmid:1689914 |
| Suzuki N et al. | Effects of a novel immunosuppressive agent, FK506, on human B cell activation. | 1990 | Clin. Exp. Immunol. | pmid:1690097 |
| McCauley J et al. | FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. | 1990 | Lancet | pmid:1690326 |
| Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
| Woo J et al. | The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. | 1990 | Scand. J. Immunol. | pmid:1690915 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| Propper DJ et al. | Low-dose FK 506 inhibits sensitisation after blood transfusions. | 1990 | Transplant. Proc. | pmid:1697114 |
| Tiebosch A et al. | Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. | 1990 | Transplant. Proc. | pmid:1697115 |
| Dammeijer PF et al. | Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. | 1990 | Transplant. Proc. | pmid:1697116 |
| Imai K et al. | Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. | 1990 | Transplant. Proc. | pmid:1697117 |
| Iga C et al. | Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. | 1990 | Transplant. Proc. | pmid:1697118 |
| Deguchi K et al. | [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. | 1990 | No To Shinkei | pmid:1697182 |
| Murase N et al. | Prevention of spontaneous diabetes in BB rats with FK 506. | 1990 | Lancet | pmid:1697397 |
| Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
| Isai H et al. | FK 506 and orthotopic liver transplantation in the rat. | 1990 | Transplant. Proc. | pmid:1699329 |
| Suzuki S et al. | In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. | 1990 | Heart Vessels | pmid:1699922 |
| Bierer BE et al. | Probing immunosuppressant action with a nonnatural immunophilin ligand. | 1990 | Science | pmid:1700475 |
| Pugh-Humphreys RG et al. | The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. | 1990 | Immunology | pmid:1696242 |
| Mochizuki M and Kawashima H | Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. | 1990 | Autoimmunity | pmid:1717007 |
| Ni M et al. | FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. | 1990 | Autoimmunity | pmid:1717008 |